Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E31.17 EPS (ttm)1.61 Insider Own0.10% Shs Outstand1.66B Perf Week1.01%
Market Cap83.19B Forward P/E28.91 EPS next Y1.74 Insider Trans29.03% Shs Float1.66B Perf Month1.46%
Income2.69B PEG2.35 EPS next Q0.42 Inst Own71.80% Short Float1.93% Perf Quarter3.61%
Sales16.21B P/S5.13 EPS this Y32.80% Inst Trans-0.02% Short Ratio4.19 Perf Half Y-6.26%
Book/sh9.25 P/B5.42 EPS next Y-4.25% ROA7.60% Target Price53.06 Perf Year23.96%
Cash/sh4.33 P/C11.59 EPS next 5Y13.25% ROE17.70% 52W Range39.95 - 56.66 Perf YTD-4.22%
Dividend1.44 P/FCF67.80 EPS past 5Y-3.60% ROI10.70% 52W High-11.44% Beta0.41
Dividend %2.87% Quick Ratio1.60 Sales past 5Y-1.50% Gross Margin73.60% 52W Low25.62% ATR0.68
Employees28000 Current Ratio1.80 Sales Q/Q-3.90% Oper. Margin22.50% RSI (14)56.28 Volatility0.81% 1.43%
OptionableYes Debt/Eq0.50 EPS Q/Q-37.50% Profit Margin16.60% Rel Volume0.62 Prev Close49.99
ShortableYes LT Debt/Eq0.48 EarningsJul 24 BMO Payout87.10% Avg Volume7.61M Price50.18
Recom2.40 SMA200.82% SMA502.70% SMA200-0.55% Volume4,709,840 Change0.38%
25-Jul-14Reiterated MKM Partners Sell $29 → $34
15-Jan-14Reiterated Argus Buy $58 → $62
10-Jan-14Upgrade Barclays Equal Weight → Overweight $52 → $65
20-Dec-13Reiterated UBS Neutral $48 → $54
29-Jul-13Reiterated Argus Buy $54
17-Jul-13Reiterated Barclays Equal Weight $42 → $45
04-Jun-13Reiterated Argus Buy $46 → $54
26-Apr-13Reiterated MKM Partners Sell $26 → $29
15-Apr-13Reiterated Barclays Equal Weight $33 → $42
25-Jan-13Reiterated UBS Neutral $34 → $36
09-Jan-12Reiterated Barclays Capital Overweight $34 → $36
19-Oct-11Initiated MKM Partners Sell $26
27-Jun-11Reiterated UBS Neutral $28 → $30
31-Mar-11Downgrade Jefferies Buy → Hold $28.50
28-Mar-11Reiterated Barclays Capital Overweight $28 → $30
22-Sep-10Reiterated Deutsche Bank Buy $28 → $31.50
01-Sep-10Reiterated UBS Neutral $26 → $27
31-Aug-10Upgrade Jefferies Hold → Buy $28.80 → $30
12-Mar-10Initiated Jefferies & Co Hold $27
16-Dec-09Initiated UBS Neutral
22-Aug-14 04:55PM  Bristol-Myers/Pfizer's Eliquis Gets Yet Another FDA Nod Zacks
21-Aug-14 04:20PM  Bristol-Myers, Celgene Pair Up for Oncology Combo Treatments Zacks
04:07PM  FDA Grants New Indication For Pfizer, Bristol-Myers Squibb Drug at Forbes
03:47PM  5 companies that will benefit from ALS awareness at MarketWatch
03:10PM  FDA clears Eliquis for new use against blood clots AP
02:44PM  FDA approves use of Eliquis to treat leg, lung clots Reuters
02:44PM  ELIQUIS Approved for Deep Vein Thrombosis and Pulmonary Embolisms 24/7 Wall St.
01:56PM  FDA OKs use of Eliquis to treat leg, lung clots Reuters
01:31PM  U.S. FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy Business Wire
20-Aug-14 08:52AM  [$$] Bristol-Myers, Celgene to Collaborate on Cancer-Treatment Study at The Wall Street Journal
08:00AM  Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis® (apixaban) at the ESC Congress 2014 Business Wire
08:00AM  Bristol-Myers Squibb and Celgene Enter Clinical Collaboration Agreement to Evaluate Immunotherapy and Chemotherapy Combination Regimen Business Wire
19-Aug-14 06:27PM  This stock may be hazardous to your financial health Talking Numbers
18-Aug-14 08:00AM  Premier Biotechnology & Anti-CTLA4 Accesswire
12-Aug-14 10:48AM  Intercept Pharma Soars On Liver-Disease Drug Data at Investor's Business Daily
08-Aug-14 05:50AM  Cramer: The Futures Don't Discriminate TheStreet
07-Aug-14 11:00AM  Leica Biosystems and Bristol-Myers Squibb Enter Into a Development and Commercialization Collaboration for Companion Diagnostics that Support Targeted Therapies PR Newswire
06-Aug-14 06:00AM  The R&D elite: America's most innovative companies at CNBC
06:00AM  The R&D elite of the market: The CNBC RQ 50 at CNBC
05-Aug-14 05:22PM  Drugmaker AstraZeneca Returns To Growth at Investor's Business Daily
07:33AM  Saving kids: When unapproved drugs are the only hope at CNBC
04-Aug-14 11:49AM  Bristol-Myers Squibb in venture to turn US research into drugs at Financial Times
02:00AM  Allied Minds and Bristol-Myers Squibb Form New Enterprise to Advance Discoveries of Biopharmaceutical Innovations at Leading U.S. Academic Research Institutions Business Wire
01-Aug-14 10:56AM  [$$] Bristol-Myers to Be Crowned With Royalties at Barrons.com
09:11AM  The R&D elite of the market: The CNBC RQ 50 at CNBC
31-Jul-14 01:30PM  Drug pricing: Bitter pill at Financial Times
01:04PM  BRISTOL MYERS SQUIBB CO Financials EDGAR Online Financials
30-Jul-14 06:48PM  Aon Names John Bruno CIO at The Wall Street Journal
29-Jul-14 01:02PM  3 Stocks Boosting The Drugs Industry Higher at TheStreet
12:53PM  Bristol-Myers Squibb Company (BMY) Highlighted As Storm The Castle Stock at TheStreet
07:00AM  European Commission Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE Business Wire
28-Jul-14 01:18PM  Pfizer Dips On BMO Downgrade at Barrons.com
12:44PM  3 Stocks Reiterated As A Buy: MU, BMY, NFLX at TheStreet
27-Jul-14 04:00PM  Drug cocktails point the way towards relief for all hepatitis C sufferers at Financial Times
25-Jul-14 01:17PM  Why Bristol-Myers Squibb Loses Out Against This Rival at Seeking Alpha
08:53AM  The Zacks Analyst Blog Highlights: Starbucks, Dunkin' Brands, Bristol-Myers Squibb, AstraZeneca and Pfizer Zacks
07:27AM  EMA recommends expanded indication for Baraclude at theflyonthewall.com
24-Jul-14 04:46PM  Bristol-Myers Squibb Company's (BMY) CEO Lamberto Andreotti Q2 2014 Results - Earnings Call Transcript Seeking Alpha
04:01PM  BioMed Realty And Bristol-Myers Squibb Sign Lease To Expand Relationship To 194,100 Square Feet At Woodside Technology Park In Redwood City, California PR Newswire
04:00PM  Bristol-Myers (BMY) Beats on Q2 Earnings, Maintains Outlook Zacks
03:30PM  [video] Bristol-Myers Q2 Sales Fall, Will Focus on Cancer Drugs at TheStreet
02:02PM  Keep Calm and Carry On, Roche Stock at Motley Fool
01:18PM  [$$] Bristol-Myers Posts Lower Profit, Revenue at The Wall Street Journal
11:42AM  Bristol-Myers Squibb's Second-Quarter Reflects a Company in Transition at Motley Fool
10:57AM  Bristol-Myers says M&A would have to be good strategic fit at theflyonthewall.com
10:53AM  Bristol 2Q net drops on lower drug sales, charges AP
10:48AM  Bristol-Myers says guidance assumes R&D credit will be extended at theflyonthewall.com
10:30AM  Bristol-Myers Squibb Co Earnings Call scheduled for 10:30 am ET today CCBN
10:20AM  Bristol-Myers Squibb Co Earnings Call scheduled for 10:30 am ET today CCBN
09:09AM  Stock Futures Steer Higher; Facebook, Skechers Nail Q2 Wins at Investor's Business Daily
08:40AM  Ford earnings, jobless claims to lift Wall Street at CNBC
08:36AM  BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E EDGAR Online
08:24AM  [$$] Bristol-Myers Posts Lower Profit, Revenue at The Wall Street Journal
08:15AM  Bristol-Myers Squibb Co Earnings Call scheduled for 10:30 am ET today CCBN
08:15AM  Caterpillar, GM, Ford earnings to lift Wall Street at CNBC
08:00AM  [video] Ford Beats, GM Stalls, Eli Lilly Reports & Jim Cramer's Bank Pick at TheStreet
07:42AM  Bristol 2Q net drops on lower drug sales, charges AP
07:39AM  Bristol-Myers profit tops forecasts, helped by newer drugs Reuters
07:31AM  Bristol-Myers Tops Earnings Estimates on Drug Sales at Bloomberg
07:30AM  Bristol-Myers Squibb Reports Second Quarter 2014 Financial Results Business Wire
07:07AM  Q2 2014 Bristol-Myers Squibb Earnings Release - Before Market Open CCBN
23-Jul-14 09:00PM  Bristol-Myers Squibb and Ono Pharmaceutical Co., Ltd. Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan Business Wire
07:03PM  Whisper Number Impact: What Will Bristol-Myers' Shares Do Post Earnings? at Seeking Alpha
03:02PM  Will Bristol-Myers Squibb (BMY) Disappoint This Earnings Season? Zacks
02:53PM  What to Watch in The Day Ahead; Thursday, July 24 Reuters
02:18PM  More Questions Raised About Boehringer Ingelheim's Pradaxa at Forbes
02:02PM  Earnings Preview: Bristol-Myers Squibb and Celgene Corporation at Motley Fool
22-Jul-14 02:44PM  3 Stocks Reiterated As A Buy: EBAY, BMY, EMC at TheStreet
06:13AM  [$$] 9 Health Care Stocks From Index-Crushing Fund at Barrons.com
21-Jul-14 12:00AM  Perrigo, Actelion Tax Targets Abroad for U.S. Drugmakers at Bloomberg
18-Jul-14 03:45PM  Bristol-Myers/Pfizer Commence Phase IV Study on Eliquis Zacks
02:37PM  What You Need to Know About Johnson & Johnson's Best-Selling Drugs at Motley Fool
17-Jul-14 08:06AM  Bristol-Myers Squibb and Pfizer Announce Enrollment of First Patient in Phase IV EMANATE Trial to Assess Effectiveness and Safety of Eliquis® (apixaban) in Patients with NVAF Undergoing Cardioversion Business Wire
16-Jul-14 02:02PM  Keep Calm and Carry On, J&J at Motley Fool
06:21AM  Cramer's Lightning Round - General Electric Needs To Bring Good Things To Life (7/15/14) at Seeking Alpha
15-Jul-14 11:13AM  Perrigo retreats after analyst sees limited potential buyers at theflyonthewall.com
14-Jul-14 05:01PM  1 Hidden Blockbuster Lurking in Merck's Pipeline? at Motley Fool
11:27AM  Is Bristol-Myers Squibb Overvalued? at Seeking Alpha
10:40AM  Should Dividend Investors Keep or Eject Bristol-Myers Squibb Co? at Motley Fool
13-Jul-14 03:32PM  This Week in Biotech: Anacor's FDA A-OK and AbbVie's Insatiable Urge to Buy Something at Motley Fool
11-Jul-14 05:01PM  1 Drug More Important to Gilead Than Sovaldi at Motley Fool
04:30PM  Bristol-Myers to Seek U.S. Approval for Immuno-Oncology Drug Zacks
11:35AM  Senators Ask Gilead To Explain Sovaldi Pricing at Investor's Business Daily
08:52AM  How Gilead Sciences Can Deliver A Double: Part Two at Forbes
10-Jul-14 06:45PM  Bristol seeks cancer drug nod Investor's Business Daily
01:07PM  Bristol-Myers Squibb Selects GEP To Provide Strategic Category Management And Related Procurement Services In Long-Term Program PR Newswire
12:43PM  Bristol-Myers announces plans for Q3 submission of Opdivo BLA at theflyonthewall.com
12:36PM  Bristol-Myers Squibb Announces Plans for Third Quarter Submission of a Biologics License Application for Opdivo® (nivolumab), an Investigational PD-1 Immune Checkpoint Inhibitor, for Previously Treated Advanced Melanoma Business Wire
10:24AM  Bristol-Myers Seeking Nivolumab Approval In Melanoma at Investor's Business Daily
09:22AM  Bristol to seek melanoma approval for Opdivo ahead of expectations Reuters
08:56AM  Top Biotech Stocks to Watch Today: Allergan, Arena Pharmaceuticals and Bristol-Myers Squibb at Motley Fool
07:30AM  Bristol-Myers Squibb Announces Plans for Third Quarter Submission of a Biologics License Application for Opdivo® (nivolumab), an Investigational PD-1 Immune Checkpoint Inhibitor, for Previously Treated Advanced Melanoma Business Wire
09-Jul-14 03:53PM  Credit Suisse names vice chairman of healthcare group -memo Reuters
03:13AM  If AbbVie Wants Shires Low Tax Rate, Price May Go Up Bloomberg
08-Jul-14 12:29PM  3 Stocks Reiterated As A Buy: BMY, CAT, CELG at TheStreet
10:40AM  Bristol-Myers Gains Japanese Approval for HCV Combo Drug Zacks
07:20AM  Bristol-Myers price target lowered to $55 from $62 at Leerink at theflyonthewall.com
07-Jul-14 06:58PM  Japan approves BMY regimen Investor's Business Daily
06:28PM  Cramer's Bristol-Myers theorem: What is it? at CNBC
06:18PM  Jazz, Novo Among Medicals Showing Healthy Action at Investor's Business Daily
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecule products, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; metabolics; immunoscience; and cardiovascular. The company's principal products are virology products comprising Baraclude, Reyataz, and Sustiva; oncology products, including Erbitux, Sprycel, and Yervoy; neuroscience products, such as Abilify; metabolics consisting of Bydureon, Byetta, Forxiga, and Onglyza/Kombiglyze; immunoscience products, including Nulojix and Orencia; and cardiovascular products, such as Avapro/Avalide, Eliquis, and Plavix. It has various products under Phase III clinical trials for the treatment of hepatitis C virus infection, including Asunaprevir; Daclatasvir; BMS-791325; and Peginterferon lambda. The company also has various products under Phase III clinical trials for treatment of cancer comprising Elotuzumab and Nivolumab. In addition, it develops Baraclude and Reyataz for pediatric extensions; Erbitux for esophageal cancer; Yervoy for melanoma, prostate cancer, and non-small-cell and small cell lung cancer; Orencia for lupus nephritis and psoriatic arthritis; and Eliquis for venous thromboembolic treatment and prevention. The company sells its products to wholesalers, and directly to distributors, retailers, hospitals, clinics, government agencies, and pharmacies. It has strategic alliances with various third parties. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
von Autenried PaulSVP, Enterp. Services & CIOAug 19Sale49.8920,000997,85137,523Aug 19 05:08 PM
Moed Samuel JSVP, Strat Plan & AnalysisJul 28Option Exercise27.0119,650530,74759,652Jul 30 04:40 PM
Moed Samuel JSVP, Strat Plan & AnalysisJul 28Sale49.3225,7521,270,03733,900Jul 30 04:40 PM
DANIELS BRIANSVP Global Dev & Med AffairsJul 01Option Exercise0.004,671096,477Jul 02 06:35 PM
ANDREOTTI LAMBERTOChief Executive OfficerMay 05Option Exercise0.0013,9900662,469May 06 09:17 PM
Elicker John ESVP Pub Affairs & Inv RelationMay 03Option Exercise0.001,509050,536May 05 05:05 PM
Moed Samuel JSVP, Strat Plan & AnalysisMay 01Option Exercise0.005,000042,595May 02 04:18 PM
JUDGE ANN POWELLSVP, Human ResourcesApr 01Option Exercise0.001,55403,693Apr 03 04:17 PM
Caldarella Joseph CSVP & ControllerMar 13Sale55.209,137504,36268,965Mar 13 04:32 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.002,739058,345Mar 12 04:54 PM
LEUNG SANDRAGeneral Counsel & SecretaryMar 10Option Exercise0.004,8780262,120Mar 12 04:52 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 10Option Exercise0.001,173037,948Mar 12 04:53 PM
Nielsen AnneChief Compliance & Ethics OffMar 10Option Exercise0.00688043,432Mar 12 04:53 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.002,739011,600Mar 12 04:53 PM
Cuss Francis MEVP & CSOMar 10Option Exercise0.002,7390239,268Mar 12 04:51 PM
DANIELS BRIANSVP Global Dev & Med AffairsMar 10Option Exercise0.002,528092,314Mar 12 04:51 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 10Option Exercise0.001,850049,399Mar 12 04:52 PM
Heller Frances KSVP, Business DevelopmentMar 10Option Exercise0.001,60904,402Mar 12 04:52 PM
JUDGE ANN POWELLSVP, Human ResourcesMar 10Option Exercise0.002,10702,107Mar 12 04:52 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.006,4100165,472Mar 12 04:50 PM
Caforio GiovanniEVP & Chief Commercial OfficerMar 10Option Exercise0.004,878068,910Mar 12 04:51 PM
Caldarella Joseph CSVP & ControllerMar 10Option Exercise0.001,850078,768Mar 12 04:51 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 10Option Exercise0.0027,6130658,396Mar 12 04:50 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Sale55.818,799491,0638,861Mar 10 04:43 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 10Sale55.52100,0005,552,260630,783Mar 10 04:40 PM
Nielsen AnneChief Compliance & Ethics OffMar 06Option Exercise0.00724042,756Mar 10 04:42 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 06Option Exercise0.002,528017,224Mar 10 04:43 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 06Option Exercise0.002,390056,064Mar 10 04:43 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 06Option Exercise0.001,043036,841Mar 10 04:42 PM
DANIELS BRIANSVP Global Dev & Med AffairsMar 06Option Exercise0.003,010090,018Mar 10 04:41 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 06Option Exercise0.001,043047,630Mar 10 04:42 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 06Option Exercise0.0029,2400738,383Mar 10 04:40 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 06Option Exercise0.007,3230159,626Mar 10 04:40 PM
Caforio GiovanniEVP & Chief Commercial OfficerMar 06Option Exercise0.002,889064,586Mar 10 04:40 PM
Caldarella Joseph CSVP & ControllerMar 06Option Exercise0.001,931077,422Mar 10 04:41 PM
Cuss Francis MEVP & CSOMar 06Option Exercise0.003,0100237,106Mar 10 04:41 PM
CORNELIUS JAMES MDirectorMar 05Sale55.82100,0005,582,000273,393Mar 05 04:40 PM
LEUNG SANDRAGeneral Counsel & SecretaryMar 03Option Exercise0.0099,9370292,758Mar 05 04:38 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 03Option Exercise0.0015,209040,530Mar 05 04:39 PM
Nielsen AnneChief Compliance & Ethics OffMar 03Option Exercise0.0013,132046,648Mar 05 04:39 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 03Option Exercise0.0017,471051,061Mar 05 04:37 PM
Cuss Francis MEVP & CSOMar 03Option Exercise0.0047,9530254,899Mar 05 04:36 PM
DANIELS BRIANSVP Global Dev & Med AffairsMar 03Option Exercise0.0050,3260103,410Mar 05 04:37 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 03Option Exercise0.00121,0140199,850Mar 05 04:35 PM
Caforio GiovanniEVP & Chief Commercial OfficerMar 03Option Exercise0.0018,875068,527Mar 05 04:36 PM
Caldarella Joseph CSVP & ControllerMar 03Option Exercise0.0031,053089,900Mar 05 04:36 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 03Option Exercise0.00423,5330912,318Mar 05 04:35 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 03Option Exercise0.0039,420068,820Mar 05 04:40 PM
Schmukler Louis SPres., Global Mfg. & SupplyFeb 28Sale54.496,088331,73614,696Feb 28 04:44 PM
Caforio GiovanniEVP & Chief Commercial OfficerFeb 24Option Exercise17.5139,363689,24691,316Feb 25 04:30 PM
Caforio GiovanniEVP & Chief Commercial OfficerFeb 24Sale54.4441,5632,262,63849,753Feb 25 04:30 PM
Elicker John ESVP Pub Affairs & Inv RelationFeb 19Sale54.229,534516,91132,740Feb 19 04:25 PM
Cuss Francis MEVP & CSOFeb 18Option Exercise28.1138,6671,086,929237,037Feb 18 05:07 PM
Cuss Francis MEVP & CSOFeb 18Sale54.6129,8001,627,360207,237Feb 18 05:07 PM
LEUNG SANDRAGeneral Counsel & SecretaryFeb 14Option Exercise28.1115,000421,650206,345Feb 18 05:07 PM
Bancroft Charles AEVP & Chief Financial OfficerFeb 14Option Exercise24.0036,251870,038130,266Feb 18 05:07 PM
Bancroft Charles AEVP & Chief Financial OfficerFeb 14Sale54.3552,9632,878,28577,303Feb 18 05:07 PM
LEUNG SANDRAGeneral Counsel & SecretaryFeb 14Sale54.2810,490569,377195,855Feb 18 05:07 PM
ANDREOTTI LAMBERTOChief Executive OfficerFeb 11Option Exercise28.11108,0003,035,880586,562Feb 11 04:30 PM
ANDREOTTI LAMBERTOChief Executive OfficerFeb 11Sale52.6686,0754,532,572500,487Feb 11 04:30 PM
Caldarella Joseph CSVP & ControllerFeb 06Option Exercise19.4226,484514,20294,826Feb 06 05:28 PM
DANIELS BRIANSVP Global Dev & Med AffairsFeb 06Option Exercise28.1118,750527,06381,989Feb 06 05:29 PM
DANIELS BRIANSVP Global Dev & Med AffairsFeb 06Sale48.9328,4401,391,43353,549Feb 06 05:29 PM
Caldarella Joseph CSVP & ControllerFeb 06Sale48.9035,4711,734,45759,355Feb 06 05:28 PM
CAMPBELL LEWIS BDirectorFeb 05Option Exercise25.702,50064,2502,500Feb 05 05:37 PM
CAMPBELL LEWIS BDirectorFeb 05Sale48.282,500120,7120Feb 05 05:37 PM
CORNELIUS JAMES MDirectorFeb 04Sale48.90100,0004,890,000373,393Feb 04 05:00 PM
Caforio GiovanniEVP & Chief Commercial OfficerJan 03Option Exercise0.007,500054,817Jan 06 05:40 PM
Cuss Francis MEVP & CSONov 02Option Exercise0.006,6660201,827Nov 04 04:20 PM
Schmukler Louis SPres., Global Mfg. & SupplyOct 03Option Exercise0.0013,934025,869Oct 04 04:19 PM
Heller Frances KSVP, Business DevelopmentOct 01Option Exercise0.004,45104,451Oct 02 04:23 PM